首页 > 文献资料
-
早泄的当前治疗策略及未来前景
-
Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the ifrst drug approved for the on?demand treatment of premature ejaculation(PE). Our objective in this study was to characterize the efifcacy of on?demand dapoxetine(30 and 60mg) and daily paroxetine(20mg) usage in treating PE. We conducted a 1 month study involving a total of 150patients. Patients were divided into three groups of 50. Group1 were treated with on?demand dapoxetine(30mg), Group2 with on?demand dapoxetine(60mg) and Group3 with daily paroxetine(20mg). Our outcome measurement was increased from baseline intravaginal ejaculatory latency time(IELT) after treatment. The IELT increased from baseline to posttreatment by 117%, 117% and 170% in the paroxetine group(P<0.01), 30mg dapoxetine group(P<0.01) and 60mg dapoxetine group(P<0.01), respectively. The increase from baseline IELT were similar for the 30mg dapoxetine and paroxetine groups(P>0.05), while the 60mg dapoxetine group had a larger posttreatment IELT increase compared with the 30mg dapoxetine(P<0.05) and paroxetine(P<0.01) groups. Dapoxetine(60mg) 1–3h before planned intercourse is a very effective treatment modality for PE. However, an on?demand dose of 30mg dapoxetine is no more effective than the currently prescribed paroxetine treatment.
